Newly Published Analytical Validation Reinforces Accuracy and Precision of MyProstateScore 2.0

A new peer-reviewed study published in Diagnostics confirms the analytical validity of MyProstateScore 2.0 (MPS2), a urine-based test designed to assess the risk of clinically significant prostate cancer. The findings reinforce MPS2’s reliability in both post-digital rectal exam (DRE) and at-home non-DRE collection settings, further solidifying its value in prostate cancer screening.

The analytical validation evaluated MPS2’s performance across a wide range of laboratory and clinical conditions, including:

• Detection sensitivity and quantification range for all 18 urinary biomarkers
• Precision across operators, equipment, reagents and runs
• Reproducibility of risk scores in clinical urine samples
• Potential interference from common urinary substances

MPS2 consistently met or exceeded the performance criteria in every category tested.

This validation builds on previous clinical studies showing MPS2’s ability to significantly outperform PSA testing in predicting high-grade prostate cancer. 

By confirming the test’s robust analytical performance, Lynx Dx has further established MPS2 as a trusted, non-invasive option for deciding whether to proceed with a biopsy—whether samples are collected in-office or at home.